Plasma sphingomyelin level as a risk factor for coronary artery disease
Plasma sphingomyelin level as a risk factor for coronary artery disease
复制标题
DOI：
10.1161/01.atv.20.12.2614
复制
发表时间：
2000-12-01
影响因子：
8.7
通讯作者：
Tall, AR
中科院分区：
文献类型：
--
作者：
Jiang, XC;Paultre, F;Tall, AR
只有一小部分动脉粥样硬化的临床并发症可以用已知的危险因素来解释。动物研究表明，血浆鞘磷脂（SM）水平与动脉粥样硬化的发展密切相关。SM携带到动脉壁的致动脉粥样硬化的脂蛋白可以被鞘磷脂酶局部水解，促进脂蛋白聚集和巨噬细胞泡沫细胞的形成。一种新的，高通量，酶法测定血浆SM水平已被开发。在一项双种族血管造影病例对照研究（279例病例和277例对照）中，血浆SM水平与冠状动脉疾病（CAD）的存在相关。冠心病患者血浆SM水平高于对照组（分别为60+/-29和49+/-21 mg/dL; P
Only a fraction of the clinical complications of atherosclerosis are explained by known risk factors. Animal studies have shown that plasma sphingomyelin (SM) levels are closely related to the development of atherosclerosis. SM carried into the arterial wall on atherogenic lipoproteins may be locally hydrolyzed by sphingomyelinase, promoting lipoprotein aggregation and macrophage foam cell formation. A novel, high-throughput, enzymatic method to measure plasma SM levels has been developed. Plasma SM levels were related to the presence of coronary artery disease (CAD) in a biethnic angiographic case-control study (279 cases and 277 controls). Plasma SM levels were higher in CAD patients than in control subjects (60+/-29 versus 49+/-21 mg/dL, respectively; P